Bayer Menopause Drug Meets Key Goal in Late-Stage Trial
By Adria Calatayud
Bayer said investigational drug elinzanetant met its primary goal by reducing symptoms linked to menopause in a late-stage clinical trial, paving the way for submissions to health authorities for approval.
The German pharmaceutical-and-agricultural group said Tuesday that elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms, also known as hot flashes, compared to placebo. The long-term safety profile observed over 52 weeks in the phase 3 trial is overall consistent with previously conducted studies, the company said.
The study comes after Bayer reported positive results for two late-stage studies of the same drug.
Bayer said it will submit data from the studies to health authorities for approval of elinzanetant for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
March 19, 2024 03:48 ET (07:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Arm Earnings: Shares Fall as 2025 Guidance Disappoints Investors
-
Occidental Earnings: CrownRock Transaction Should Still Close, but Not Until the Third Quarter
-
After Earnings, Is Apple Stock a Buy, a Sell, or Fairly Valued?
-
Uber Earnings: Network Effect Continues to Drive Profitable Growth for Uber
-
Undervalued by 28%, This Stock Is a Buy for Patient Investors
-
10 Best Growth Stocks to Buy for the Long Term
-
The Best Technology Stocks to Buy
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?